Companies: 10,795·Total market cap: $144.5T
Medpace Holdings, Inc.

Medpace Holdings, Inc.

MEDPNASDAQHealthcare● Active
$454.25
$-4.44(-0.97%)
Market Cap$13.0B
P/E Ratio
52W High$628.916
52W Low$293.2

Medpace Holdings, Inc. (MEDP) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

medp · stock forecast · 19 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 19 Wall Street analysts in the past 3 months

SellBuy

Hold

19 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
6
Hold
12
Sell
1
Strong Sell
0
Total: 19 · Buy rate: 31.6%

12-Month Price Target

High

$582

Consensus

$499

+9.8% upside

Low

$400

Median: $484 · Last Close: $454.25

The Medpace Holdings, Inc. (MEDP) analyst consensus is Hold, based on ratings from 19 Wall Street analysts over the past 3 months. The average 12-month MEDP price target is $498.86, representing +9.8% upside from the current price of $454.25.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $499 (9.8%)

Consensus Target

$498.86

9.8% upside

High Target

$582

28.1%

Low Target

$400

-11.9%

Current Price

$454.25

as of today

Based on analyst price targets, the MEDP stock price prediction for the next 12 months ranges from $400 to $582. The consensus MEDP price forecast of $498.86 implies 9.8% upside from the current price of $454.25.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$466.952.80%

1-day model range: $465.6–$468.3. Peak: $468.3 (+2.80%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$671+47.7%
2028$879+93.4%
2029$1055+132.4%
2030$1194+162.8%
2031+185.1%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

57%0%43%
8Buy
0Neutral
6Sell
RSI (14)76.8Overbought
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · MEDP · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$452.16BUY
MA 10$444.60BUY
MA 20$432.89BUY
MA 50$454.79SELL
MA 100$479.40SELL
MA 200$512.64SELL
Current $MEDP · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$451.64BUY
EMA 10$445.73BUY
EMA 20$441.10BUY
EMA 50$450.82BUY
EMA 100$470.16SELL
EMA 200$472.36SELL
Current $MEDP · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Barclays2026-04-24
Maintains
Equal WeightEqual Weight
BMO Capital2026-04-24
Maintains
Market PerformMarket Perform
RBC Capital2026-04-24
Maintains
OutperformOutperform
Baird2026-04-24
Maintains
OutperformOutperform
Barclays2026-03-06
Upgrade ↑
UnderweightEqual Weight
TD Cowen2026-02-18
Upgrade ↑
SellHold
Jefferies2026-02-13
Upgrade ↑
HoldBuy
Truist Securities2026-02-11
Maintains
HoldHold
Leerink Partners2026-02-11
Maintains
Market PerformMarket Perform
Barclays2026-02-11
Maintains
UnderweightUnderweight

Wall Street analysts have recently issued updated ratings on Medpace Holdings, Inc. (MEDP) stock. Of the recent 86 rating actions, 13 were upgrades and 16 were downgrades. 19 analysts currently cover MEDP.

Analyst Recommendation Trends

Buy ratings02↑ +2
Hold ratings22
Sell ratings00

MEDP analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 2 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$2.8B

↓ 12.4% YoY

Revenue Next Year

$2.9B

↑ 4.9% YoY

EPS This Year

$16.99

EPS Next Year

$18.37

↑ 8.2% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast MEDP EPS of $16.99 for the current fiscal year, based on estimates from 9 analysts. The MEDP revenue forecast is $2.8B for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The MEDP stock forecast is supported by two independent data sources: analyst consensus ratings from 19 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus MEDP price target is $498.86 (+9.8% upside), with an analyst consensus of Hold.

The MEDP short-term stock prediction for tomorrow is $466.95 (+2.80%). The MEDP stock price prediction for 2027 estimates an average of $671. The MEDP stock prediction for 2030 projects a range of $1156–$1231.

Medpace Holdings, Inc. trades on NASDAQ under the ticker MEDP. The MEDP stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 32% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

MEDP forecast · 8 questions

According to 19 Wall Street analysts, the average 12-month MEDP price target is $498.86, with a high forecast of $582.00 and a low of $400.00. The median price target is shown in the chart above when available. This implies +9.8% potential upside from the current price of $454.25.

MEDP price targetWhat is MEDP price targetMEDP analyst price targetMEDP 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.